Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer.

Details

Ressource 1Request a copyDownload: BIB_8A43127D5754.P001.pdf (1173.71 [Ko])
State: Deleted
Version: author
Serval ID
serval:BIB_8A43127D5754
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer.
Journal
Future Oncology
Author(s)
Toriola A.T., Tolockiene E., Schock H., Surcel H.M., Zeleniuch-Jacquotte A., Wadell G., Toniolo P., Lundin E., Grankvist K., Lukanova A.
ISSN
1744-8301 (Electronic)
ISSN-L
1479-6694
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
10
Number
3
Pages
377-384
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
BACKGROUND: We investigated whether the free β-human chorionic gonadotropin (free β-hCG) would provide additional information to that provided by total hCG alone and thus be useful in future epidemiological studies relating hCG to maternal breast cancer risk.
MATERIALS & METHODS: Cases (n = 159) and controls (n = 286) were a subset of our previous study within the Northern Sweden Maternity Cohort on total hCG during primiparous pregnancy and breast cancer risk.
RESULTS: The associations between total hCG (hazard ratio: 0.79; 95% CI: 0.49-1.27), free β-hCG (hazard ratio: 0.85; 95% CI: 0.33-2.18) and maternal risk of breast cancer were very similar in all analyses and mutual adjustment for either one had minor effects on the risk estimates.
CONCLUSION: In the absence of a reliable assay on intact hCG, total hCG alone can be used in epidemiological studies investigating hCG and breast cancer risk, as free β-hCG does not appear to provide any additional information.
Pubmed
Web of science
Create date
20/06/2014 17:42
Last modification date
20/08/2019 14:49
Usage data